shRNA/miRNA AAV Production Service:
Adeno-associated virus (AAV) is a small virus (20 nm in diameters) replication-defective, nonenveloped virus, which infects humans and some other primate species. AAV is not currently known to cause disease and consequently the virus causes a very mild immune response. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell.
With our proprietary genetically engineered AAV·HT™ packaging cell, we are offering shRNA/miRNA rAAV (conventional single stranded rAAV or double-stranded rAAV also called self-complementary rAAV*) production services for efficient silencing in vitro and in vivo.
If commercial shRNAs or siRNAs of your target gene are not available or non-functional, or your project requires special design for further development, we offer special shRNA design without additional charge!
With our proprietary genetically engineered AAV·HT™ packaging cell, we are offering custom shRNA rAAV vector production services (conventional single stranded or double-stranded also known as self-complementary**) listed below to fit your different research needs.
| Catalog # | Service Items | Final Deliverable* | rAAV Purity | Lead Time |
| SL100810 | shRNA rAAV Production, Full Service, Large Scale |
1.0 ml at >1E+13 VG/mL | In Vivo Grade | 3~4 weeks |
| SL100871 | shRNA rAAV Production, Full Service, Medium Scale |
0.2 ml at >1E+13 VG/mL | In Vivo Grade | 3~4 weeks |
| SL100874 | shRNA rAAV Production, Full Service, Pilot Scale |
0.1 ml at >1E+13 VG/mL | In Vivo Grade | 3~4 weeks |
| SL100872 | shRNA rAAV Packaging Service, Large Scale | 1.0 ml at >1E+13 VG/mL | In Vivo Grade | 1~2 weeks |
| SL100873 | shRNA rAAV Packaging Service, Medium Scale |
0.2 ml at >1E+13 VG/mL | In Vivo Grade | 1~2 weeks |
| SL100875 | shRNA Validation Service | >6xshRNA rAAV cis Plasmids with >1 Plasmid at 80% KD | N/A | 2~3 weeks |
Large shRNA AAV cis vector collection offers tremendous flexibility for choosing a specific promoter and reporter.
Single-promoter shRNA/miRNA AAV cis vector |
Dual-promoter shRNA/miRNA rAAV cis vector |
|||
| Promoterless CMV CAG H1 U6 Synapsin UBC EF1α ALB(1.4) ApoE/AAT1 CaMKII ELA1 Enh358MCK cTNT GFAP MBP SST TBG αMHC hRPE mIP1 tMCK |
Promoterless CMV CAG H1 U6 Synapsin UBC EF1α ALB(1.4) ApoE/AAT1 CaMKII ELA1 Enh358MCK cTNT GFAP MBP SST TBG αMHC hRPE mIP1 tMCK |
CMV CAG H1 U6 Synapsin UBC EF1α CaMKII cTNT GFAP |
eGFP RFP mRFP mCherry tdTOMATO TurboGFP eYFP Venus Luc LacZ |
|
Required Materials: GenBank access #, target sequence, or validated siRNA, shRNA sequence; miRNA accession #, pre-miRNA or mature miRNA.
Deliverables: Total >1.0 mL at >1E+13 VG/mL** shRNA/miRNA rAAV for large scale production.
With our proprietary genetically engineered AAV·HT™ packaging cell and a modified rAAV cis plasmid, the shRNA/miRNA rAAV yield is easy to reach super high level——–total 1E+15 VG.
For super high level rAAV production up to 1E+15 VG, please contact us to request a quote.
* Some terms may apply for custom double-stranded or self-complementary rAAV production service.
** Final viral yield may depend on the transgene in the virus.
To learn more, please visit http://signagen.com/shRNA-miRNA-AAV-Production-Service